Reshape Lifesciences INC 8-K filings

Vyome Holdings reports Q1 2026 financial results, highlighting a strengthened cash position and progress on its lead clinical asset, VT-1953.

Vyome Holdings, Inc. announced a significant reduction in its authorized common stock from 300 million to 50 million shares, alongside the election of new directors and ratification of auditors.

Livechain, a Vyome subsidiary, completed an all-stock acquisition of Humanyze's senior secured debt, positioning itself in the AI HR market and paving the way for a potential national exchange uplisting in 2026.

An independent analysis projects Vyome Holdings' lead clinical candidate, VT-1953, for malignant fungating wounds, to reach a U.S. asset value of $1 billion after successful Phase 3 completion, with peak annual sales of $696 million.

Vyome Holdings' subsidiary, LiveChain, Inc., entered a binding letter of intent to acquire a senior secured convertible note from Remus Capital, issued by Humanyze, in exchange for LICH common stock.

Vyome Holdings announced its third fiscal quarter 2025 financial results and significant corporate and clinical milestones, including positive interim Phase 2 data for VT-1953 and an AI strategy launch.

Vyome Holdings, Inc. announced the results of its 2025 Annual Meeting of Stockholders, including the election of Class I directors and approval of its 2025 Equity Incentive Plan.

Vyome Holdings, Inc. announced the acquisition of Oculo, Inc., an MIT AI startup, and the launch of a new business unit focused on AI-driven inflammation treatment.

Vyome Holdings, Inc. filed an amendment to correct calculations in its unaudited pro forma condensed combined financial statements related to its merger with ReShape and concurrent financing.

Vyome Holdings, Inc. (formerly ReShape Lifesciences) finalized its merger with Vyome Therapeutics, securing $6.9 million in concurrent financing to advance its clinical-stage drug candidates.

Vyome Holdings, Inc. increased its at-the-market offering to $12 million and changed its independent registered public accounting firm.

Vyome Holdings, formerly ReShape Lifesciences, completed its merger with Vyome Therapeutics, Inc., effected a 1-for-4 reverse stock split, and sold its non-cash assets for $2.25 million.

ReShape Lifesciences Inc. stockholders approved the sale of substantially all assets and amendments related to its proposed merger with Vyome Therapeutics.

ReShape Lifesciences Inc. adjourned its special stockholder meeting to solicit further votes on the proposed asset sale and merger, while other proposals, including a reverse stock split authorization, were approved.

ReShape Lifesciences Inc. announced a proposed reverse merger with Vyome Therapeutics, Inc. and an asset sale to Ninjour Health International Limited, aiming to establish a new US-India healthcare platform focused on immuno-inflammation assets.

ReShape Lifesciences Inc. has provided a $200,000 promissory note to Vyome Therapeutics, Inc. to support working capital and merger-related expenses, advancing their previously announced merger agreement.

ReShape Lifesciences Inc. has successfully increased its stockholders' equity above the Nasdaq minimum requirement through recent stock sales, mitigating an immediate delisting threat, though continued listing is not guaranteed.

ReShape Lifesciences Inc. has successfully closed a public offering of common stock, raising approximately $2.6 million in gross proceeds to support general corporate purposes and its proposed merger with Vyome Therapeutics, Inc.

ReShape Lifesciences Inc. announced the pricing of a public offering of 1,054,604 common shares at $2.50 per share, expecting gross proceeds of $2.64 million, while also updating its ongoing at-the-market offering.

ReShape Lifesciences Inc. has entered into an agreement with Maxim Group LLC to sell up to $9.7 million of its common stock through an at-the-market offering, providing flexible access to capital.

ReShape Lifesciences Inc. has received a notice from Nasdaq indicating its securities will be delisted due to non-compliance with the minimum stockholders' equity requirement, prompting the company to initiate an appeal.

ReShape Lifesciences is undergoing a major strategic transformation, merging with clinical-stage pharmaceutical company Vyome Therapeutics and divesting its core weight-loss assets, while both entities face substantial financial losses and going concern warnings.

ReShape Lifesciences implemented a 1-for-25 reverse stock split, effective May 9, 2025, to increase its stock price and maintain Nasdaq compliance.

ReShape Lifesciences Inc. and Ninjour Health International Limited amended their Asset Purchase Agreement, reducing the exercise price to $2.25 million and extending the termination date to June 30, 2025.

ReShape Lifesciences has entered into a promissory note to loan up to $400,000 to Vyome Therapeutics and extended the termination date of their merger agreement to June 30, 2025.

ReShape Lifesciences Inc. stockholders approved a reverse stock split, warrant exercisability, and equity purchase agreement at a special meeting on April 1, 2025.

Gary Blackford resigns from ReShape Lifesciences' Board of Directors, leading to a temporary non-compliance with Nasdaq's audit committee composition requirements.

ReShape Lifesciences has announced the pricing of a $6.0 million public offering of units, each consisting of common stock (or pre-funded warrants) and warrants.

ReShape Lifesciences has amended its convertible note agreement with Ascent Partners Fund, extending the maturity date and modifying prepayment terms.

ReShape Lifesciences has entered into an agreement for a $5 million equity line of credit to support working capital and general corporate purposes.